Allogeneic islet transplantation has progressed immensely over the last decades.Although there is evidence that 73% of patients that underwent the intervention requiredre-infusion and only 8% remained insulin independent after 20 years, this procedure hasshown to be safe and well-suited for patients with brittle diabetes and severehypoglycemia. The gene discussed is INS; the disease is diabetes mellitus.